
	Three Months Ended March 31,
	2025		2024
Numerator:
Income (loss) from continuing operations	$	35,548	$	(71,105)
Less: Net income attributable to noncontrolling interests	213		378

Net income (loss) from continuing operations available to common stockholders, basic	35,335		(71,483)
Add: Interest expense and amortization of debt discount and issuance costs for exchangeable notes, net of tax	4,203		—

Net income (loss) from continuing operations available to common stockholders, diluted	$	39,538	$	(71,483)
Denominator:
Basic weighted-average common shares outstanding	386,271		379,774
Add: Dilutive effect of stock options and restricted stock awards	12,396		—
Add: Dilutive effect of exchangeable notes	56,593		—

Diluted weighted-average common shares outstanding	455,260		379,774
Income (loss) per share from continuing operations:
Basic	$	0.09	$	(0.19)
Diluted	$	0.09	$	(0.19)

Basic earnings per share is computed by dividing net income from continuing operations available to common stockholders by the weighted-average number of common shares outstanding during each period. Diluted earnings per share is computed by dividing net income from continuing operations available to common stockholders by the weighted-average number of common shares outstanding plus the effect of all dilutive common stock equivalents during each period. The diluted weighted-average common shares outstanding calculation excludes 5 million of dilutive stock options and restricted stock awards for the three months ended March 31, 2024, as their effect would be anti-dilutive given the net loss incurred in the period. The calculation of diluted weighted-average shares excludes the impact of 3 million of anti-dilutive common stock equivalents for the three months ended March 31, 2024. The impact of anti-dilutive common stock equivalents for the three months ended March 31, 2025 is not material.

We have used the if-converted method for calculating any potential dilutive effect of the Exchangeable Notes on our diluted net income per share. Under the if-converted method, the 2025 Exchangeable Notes are assumed to be converted at the beginning of each period and the 2026 Exchangeable Notes are assumed to be converted at the beginning of the 2025 period and at the issuance date of March 19, 2024 for the 2024 period. The resulting common shares are included in the denominator of the diluted earnings per share calculation for the entire period being presented and interest expense, net of tax, recorded in connection with the Exchangeable Notes is added back to the numerator, only in the periods in which such effect is dilutive. The approximately 57 million resulting common shares related to the Exchangeable Notes for the three months ended March 31, 2024, are not included in the dilutive weighted-average common shares outstanding calculation as their effect would be anti-dilutive given the net loss incurred in the period.